



FOR IMMEDIATE RELEASE

Contact: Beth Osowski, Director of Communications
Restless Legs Syndrome Foundation
RLS Foundation Telephone: 507-287-6465
Toll Free Information Request: 877-463-6757 (877-INFO-RLS)
Email: rlsfoundation@rls.org
Website: www.rls.org

RLS FOUNDATION PRESENTS FIRST SCIENCE AWARD TO DR. RONALD KRALL

ROCHESTER, MN – November 15, 2005 – The Restless Legs Syndrome Foundation, through its Medical Advisory Board, is pleased to announce that Ronald L. Krall, MD has been selected as the first recipient of the Restless Legs Syndrome Foundation Science Award for his outstanding support of research that has advanced the understanding of restless legs syndrome (RLS).

As Senior Vice President of WorldWide Development at GlaxoSmithKline, Dr. Krall has supported the extensive development and execution of several epidemiological studies, including the “REST” Studies, which have determined for the first time, using full RLS diagnostic criteria, critical information on the actual prevalence of RLS both in Europe and the United States. These studies also provided an integral view into the nature of RLS, documenting the degree of distress and the adverse effects on quality of life that people with RLS experience in both Europe and the United States. The most recent REST studies now provide information on prevalence of RLS in children and its possible relation to attention deficit disorder. All of these studies have been particularly remarkable for their careful execution involving extensive collaboration with RLS experts.

“I have had the pleasure of collaborating with the research team selected by Dr. Krall and GlaxoSmithKline in designing and executing these epidemiological studies,” said Dr. Richard Allen, a member of the RLS Foundation’s Medical Advisory Board. “These studies not only firmly established the prevalence of RLS but also recognized the spectrum of severity of the disorder. The studies included special attention to prevalence and impact of clinically significant RLS, demonstrating the profound disruption of quality of life caused by RLS. Clinically significant RLS

- Continued -

reduces quality of life as much or more than most other chronic disorders such as type 2 diabetes, osteoarthritis with hypertension, and depression.” Dr. Allen identifies the impact of these studies for patient treatment. “At the time of these studies RLS was largely under-diagnosed and untreated. Thus these studies demonstrated the large unmet medical need for diagnosis and treatment of RLS.”

In his role at GlaxoSmithKline, Dr. Krall manages a 4500 employee group with seven sites in the field of Worldwide Clinical Development, Regulatory Affairs, Clinical Safety, and Biometric Data Sciences. With more than 20 years of professional experience, Dr. Krall is an accomplished leader in the research and development of pharmaceutical medications.

In addition to his corporate position, since 1983 Dr. Krall has served as Adjunct Assistant Professor of Neurology at the University of Rochester in New York. Dr. Krall is a member of several professional societies including the American Academy of Pharmaceutical Physicians, Faculty of Pharmaceutical Medicine (UK), American Academy of Neurology (Fellow), American Society of Clinical Pharmacology & Therapeutics, and the Drug Information Association. Among his many prestigious community and professional activities, Dr. Krall currently serves as President of the Board of Directors of the National Sleep Foundation.

The RLS Foundation is pleased to recognize Dr. Krall and his efforts and support which have led to significant advances in understanding RLS. Dr. Richard Allen and Ms. Georgianna Bell, Executive Director of the RLS Foundation, will present the award to Dr. Krall on Monday, November 14, 2005 at the Society for Neuroscience Annual Meeting at the Renaissance Hotel in Washington, D.C.

Disclosure statement: GlaxoSmithKline is a Gold Level Sponsor with an unrestricted educational grant to the RLS Foundation. The decision to select Dr. Krall for the Restless Legs Syndrome Foundation Science Award was made independently of any corporate relationship.

###